Bristol Myers strikes $13B MyoKardia buyout to gain heart drug As Sanofi CSO Nabel hits the exit, former I&I head Nestle steps up Avrobio bags gene therapy to join Regenxbio and Sangamo in race Sponsored: Xevinapant’s 3-year data make waves in head and neck cancer at ESMO 2020 Foghorn blows its klaxon, gunning for a $100M IPO hot on the heels of its Merck deal Biomarin snags stem cell pioneer Kevin Eggan to lead early R&D ProQR nabs former Lucentis developer as new CSO NIH to award $234M to support projects bringing COVID-19 testing to underserved populations Trump takes Regeneron's antibodies, Gilead's remdesivir, dexamethasone in first days of COVID-19 hospital stay Featured Story | By Nick Paul Taylor Bristol Myers Squibb has struck a deal to acquire MyoKardia for $13.1 billion. The all-cash takeover will see Bristol Myers pay a 61% premium to MyoKardia’s closing price on Friday to secure a heart disease drug that is nearing a filing for approval. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus After eight years as Sanofi’s chief scientist, Gary Nabel, M.D., Ph.D., is calling it quits. He hands the reins to Frank Nestle, M.D., previously the company’s global head of immunology and inflammation and chief scientific officer in North America, Sanofi said in a tweet Friday. read more By Nick Paul Taylor Avrobio has licensed a Hunter syndrome lentiviral gene therapy from the University of Manchester. The deal positions Avrobio to join Regenxbio and Sangamo Therapeutics in the race to develop gene therapies for use in patients with the rare disorder. read more Sponsored by: Debiopharm Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally advanced head and neck cancer by 50%.. This first-in-class molecule showed it could improve long-term outcomes in hard-to-treat patients, becoming the first in decades to demonstrate a survival benefit in this group. read more By Ben Adams Preclinical biotech Foghorn Therapeutics is aiming for a $100 million IPO, but don’t be surprised it if goes the way of many other biotech listings and shoots far north of that. read more By Amirah Al Idrus Nearly two months after the FDA nixed its hemophilia gene therapy, BioMarin has a new early research chief. Kevin Eggan, Ph.D., a Harvard University professor and recipient of a MacArthur “genius” grant, will lead the company’s discovery programs, steering the development of its future pipeline. read more By Ben Adams Dutch RNA specialist ProQR has hired eye disease specialist Naveed Shams, M.D., Ph.D., as its new chief scientific officer. read more By Conor Hale Through its COVID-19 diagnostic development initiative, the NIH announced it has awarded nearly $234 million to improve access to testing among underserved and vulnerable populations. read more By Kyle Blankenship President Donald J. Trump's medical team is navigating an uncertain COVID treatment course for the nation's now-hospitalized leader. With Trump's symptoms "up and down," his physicians are throwing the kitchen sink at the virus, including a steroid therapy typically reserved for the most dire cases. read more Resources Sponsored by: EVERSANA An integrated compliance model can be the competitive differentiator to commercialization and move the needle from cost center to value. Learn How. Sponsored by: Catalent Learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools. Sponsored by: Catalent This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. Sponsored by: Formedix Learn how to save time and reduce costs and complexity by streamlining the clinical trial process. Sponsored by: LabVantage Want to leapfrog lengthy LIMS deployments and position your pharmaceutical lab for success? Find out how with LabVantage Solutions. Sponsored by: Thermo Fisher Scientific Learn how to safeguard supply, improve distribution and reduce program costs and risks Sponsored by: Clinical Ink Learn how the right data capture solution can prompt the patient to follow the correct procedures and automatically sort the responses, according to protocol. Sponsored by: Guidehouse While COVID-19 has shifted the rules of the healthcare industry, research shows there was already progress on changes being made for how pharma companies are launching products. Sponsored by: Blue Matter Consulting Senior executives from 16 biopharma companies share their thoughts on how COVID-19 will change how the industry engages with its customers. Sponsored by: LexisNexis Risk Solutions A complete Life Science Industry Snapshot in One Report Sponsored by: Evidation Health Achieving patient centricity depends on evolving how evidence is generated. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: 4G Clinical This white paper addresses the complexity of basket and umbrella designs, and how modern technology is critical to run flexible, agile and quality-driven trials. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Medtech Innovation Week October 19-22 Drug Development Immersion: Live, Online Course October 21-22, 2020 | 9am - 3:30pm ET Become Fluent In Drug Development With Our Industry Expert October 21-22, 2020 | 9am - 3:30pm ET Learn How To Bring A Drug Successfully To Market Oct 21-22, 2020 | Live, Online BioBasics 101: The Biology of Biotech for the Non-Scientist: Live, Online Course November 12-13, 2020 | 9am - 3:30pm ET Drug Development Boot Camp® VIRTUAL 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now | Due to COVID19 provisions – training will be conducted VIRTUALLY | Same excellent total immersion training in new medicine development will be made available to experts who want to make a difference to patients. | 